These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 32631835)

  • 21. Regulatory T Cell Dysfunction in Idiopathic, Heritable and Connective Tissue-Associated Pulmonary Arterial Hypertension.
    Huertas A; Phan C; Bordenave J; Tu L; Thuillet R; Le Hiress M; Avouac J; Tamura Y; Allanore Y; Jovan R; Sitbon O; Guignabert C; Humbert M
    Chest; 2016 Jun; 149(6):1482-93. PubMed ID: 26836928
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Screening for connective tissue disease in pulmonary arterial hypertension.
    Pagán RJ; Lee AS; Austin CO; Burger CD
    South Med J; 2014 Oct; 107(10):666-9. PubMed ID: 25279875
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tadalafil in idiopathic or heritable pulmonary arterial hypertension (PAH) compared to PAH associated with connective tissue disease.
    Galiè N; Denton CP; Dardi F; Manes A; Mazzanti G; Li B; Varanese L; Esler A; Harmon C; Palazzini M
    Int J Cardiol; 2017 May; 235():67-72. PubMed ID: 28279499
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Value of cardiopulmonary exercise testing in comparing cardio-pulmonary function among patients with three kinds of pulmonary artery hypertension].
    Zhao Q; Liu Z; Ma X; Zhao Z; Luo Q; Gu Q; Xiong C; Zhang H; Wang Y
    Zhonghua Yi Xue Za Zhi; 2015 Nov; 95(44):3598-601. PubMed ID: 26813372
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Survival in rheumatoid arthritis-associated pulmonary arterial hypertension compared with idiopathic pulmonary arterial hypertension.
    Sadeghi S; Granton JT; Akhavan P; Pasarikovski CR; Roos AM; Thenganatt J; Moric J; Johnson SR
    Respirology; 2015 Apr; 20(3):481-7. PubMed ID: 25583377
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.
    Denton CP; Humbert M; Rubin L; Black CM
    Ann Rheum Dis; 2006 Oct; 65(10):1336-40. PubMed ID: 16793845
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum uric acid is associated with disease severity and may predict clinical outcome in patients of pulmonary arterial hypertension secondary to connective tissue disease in Chinese: a single-center retrospective study.
    Wang J; Wang Y; Li X; Huang Y; Sun X; Wang Q; Zhang M
    BMC Pulm Med; 2020 Oct; 20(1):272. PubMed ID: 33076877
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pulsatile haemodynamic parameters are predictors of survival in paediatric pulmonary arterial hypertension.
    Douwes JM; Roofthooft MT; Bartelds B; Talsma MD; Hillege HL; Berger RM
    Int J Cardiol; 2013 Sep; 168(2):1370-7. PubMed ID: 23340486
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of ambrisentan in Chinese patients with connective tissue disease-pulmonary arterial hypertension: a post-hoc analysis.
    Li M; Jing ZC; Li Y; Huo Y; Yu Z; Zhang G; Zhu P; Liu J; Ji Q; Wu B; Zhong J; Wang P; Zhu W; Zeng X
    BMC Cardiovasc Disord; 2020 Jul; 20(1):339. PubMed ID: 32680480
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Circulating markers of inflammation and angiogenesis and clinical outcomes across subtypes of pulmonary arterial hypertension.
    Hirsch K; Nolley S; Ralph DD; Zheng Y; Altemeier WA; Rhodes CJ; Morrell NW; Wilkins MR; Leary PJ; Rayner SG
    J Heart Lung Transplant; 2023 Feb; 42(2):173-182. PubMed ID: 36470771
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictors of Long-term Outcomes in Patients With Connective Tissue Disease Associated With Pulmonary Arterial Hypertension.
    Nakayama K; Nakajima Y; Tanaka R; Hirata KI; Emoto N
    J Clin Rheumatol; 2021 Dec; 27(8):e371-e377. PubMed ID: 32511146
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical characteristics and survival of pulmonary arterial hypertension associated with three major connective tissue diseases: A cohort study in China.
    Zhao J; Wang Q; Liu Y; Tian Z; Guo X; Wang H; Lai J; Huang C; Yang X; Li M; Zeng X
    Int J Cardiol; 2017 Jun; 236():432-437. PubMed ID: 28159359
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-Term Outcomes in Patients With Connective Tissue Disease-Associated Pulmonary Arterial Hypertension in the Modern Treatment Era: Meta-Analyses of Randomized, Controlled Trials and Observational Registries.
    Khanna D; Zhao C; Saggar R; Mathai SC; Chung L; Coghlan JG; Shah M; Hartney J; McLaughlin V
    Arthritis Rheumatol; 2021 May; 73(5):837-847. PubMed ID: 33538058
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease.
    Oudiz RJ; Schilz RJ; Barst RJ; Galié N; Rich S; Rubin LJ; Simonneau G;
    Chest; 2004 Aug; 126(2):420-7. PubMed ID: 15302727
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pulmonary arterial hypertension complicating connective tissue diseases.
    Hassoun PM
    Semin Respir Crit Care Med; 2009 Aug; 30(4):429-39. PubMed ID: 19634082
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Functional class improvement and 3-year survival outcomes in patients with pulmonary arterial hypertension in the REVEAL Registry.
    Barst RJ; Chung L; Zamanian RT; Turner M; McGoon MD
    Chest; 2013 Jul; 144(1):160-168. PubMed ID: 23429998
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical characteristics and survival of Japanese patients with connective tissue disease and pulmonary arterial hypertension: a single-centre cohort.
    Shirai Y; Yasuoka H; Okano Y; Takeuchi T; Satoh T; Kuwana M
    Rheumatology (Oxford); 2012 Oct; 51(10):1846-54. PubMed ID: 22740623
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The longitudinal use of EmPHasis-10 and CAMPHOR questionnaire health-related quality of life scores in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Hendriks PM; van Thor MCJ; Wapenaar M; Chandoesing P; van den Toorn LM; van den Bosch AE; Post MC; Boomars KA
    Respir Med; 2021 Sep; 186():106525. PubMed ID: 34218166
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease.
    Badesch DB; Hill NS; Burgess G; Rubin LJ; Barst RJ; Galiè N; Simonneau G;
    J Rheumatol; 2007 Dec; 34(12):2417-22. PubMed ID: 17985403
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk assessment and survival of patients with pulmonary hypertension: Multicenter experience in Turkey.
    Yaylalı YT; Başarıcı I; Kılıçkıran Avcı B; Meriç M; Sinan ÜY; Şenol H; Küçükoğlu MS; Öngen Z
    Anatol J Cardiol; 2019 Jun; 21(6):322-330. PubMed ID: 31142721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.